Capitol 982x327px

2015 ACKC
Campaign for
Research Funding

Annual campaign to get a
$15 million appropriation
for kidney cancer research

Sign up for Campaign 2015 →

Holding Hand 982x327px

Patient Guides:
Taking Charge of
Kidney Cancer

ACKC’s online pamphlets
inform and empower patients
and their caregivers

View the guides →

Researcher A 982x327px

Support ACKC

ACKC is the only major
kidney cancer grassroots
lobbying organization
raising money that goes
predominantly to fund
kidney cancer research

Donate now →

ACKC Point of View

The Cost of Cancer Medication

Why are cancer drug prices skyrocketing? What can be done to rein in costs when drug companies are a “corporate monopoly” with the highest profits of any industry? The patient power of grass-roots groups such as ACKC may hold the solution, says Hagop Kantarjian, M.D., a leader in the in the fight to lower drug costs. Full article coming soon…


  • Launching New Website

    December 7, 2014

    Today ACKC is launching its new website, updating older material and adding new content, which we will continue to do in the future. Two new features on the Homepage are “News” and “Point of View” essays. News will commence with two articles, one highlighting two studies on the use of sunitinib (Sutent) in the elderly,… More →

  • ACKC’s Advocacy Campaign Pays Off!

    December 6, 2014

    Maria Czyzyk-Krzeska of the University of Cincinnati received a two-year, IDEA grant of $474,562 from the Department of Defense to work on the effects of tobacco smoke on growth of clear cell renal cell carcinoma (ccRCC). Smoking is the major risk factor in getting kidney cancer, but the genetic signaling in RCC that is caused… More →

  • Sutent and the Elderly Patient: A Case for a Lower Dosage?

    December 5, 2014

    A recent original study reported in Clinical Genitourinary Cancer ®, June, 2014, Vol. 12, No.3 provides a ray of hope for elderly patients with metastatic RCC. Led by Dr. Ugo De Giorgi and a team of Italian oncologists, a retrospective study of 185 patients revealed that an alternative regimen of up to half the standard… More →